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Edited by Laszlo NagyAbstract Various isoforms of adiponectin circulate in the plas-
ma. We puriﬁed high molecular weight (HMW) adiponectin
from human plasma. HMW adiponectin was observed to activate
AMP-activated protein kinase (AMPK), thereby increasing the
phosphorylation of eNOS and NO production in endothelial
cells. On the other hand, cells preincubated with HMW adipo-
nectin had reduced TNFa-induced NF-jB activation. HMW
adiponectin by itself was found to modestly activate NF-jB,
which was signiﬁcantly enhanced by inhibition of AMPK/eNOS
activation. Thus, HMW adiponectin might have dual action,
both pro and anti-inﬂammatory. An initial period of NF-jB acti-
vation by HMW adiponectin might be proinﬂammatory, but it
could be counteracted by activation of AMPK/eNOS, which lead
to a potential reduction in a second activation of NF-jB against
inﬂammatory stimuli.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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cells1. Introduction
Adiponectin is an adipocyte-speciﬁc protein that enhances
insulin sensitivity and promotes lipid metabolism [1,2]. Adipo-
nectin circulates in plasma as three forms: a trimer (low molec-
ular weight: LMW), a hexamer (trimer–dimer) of medium
molecular weight (MMW), and a larger multimeric high
molecular weight (HMW) form [3–6]. A proteolytic cleavage
product of adiponectin, known as globular adiponectin
(gAd), also appears to circulate in human plasma [7]. The bio-
logic activity of each isoform has not been ﬁrmly established,
but it appears that HMW adiponectin has a beneﬁcial role in
humans and rodents with regard to prevention against the
development of atherogenesis. Experimental and clinical data
suggest that the oligomeric complex distribution of adiponec-
tin is essential for its anti-diabetic and anti-atherogenic activity
[8,9]. Thus, we obtained HMW adiponectin from human plas-*Corresponding author. Fax: +81 282 86 4632.
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gated its eﬀect on vascular endothelial cells. In the present
study, we evaluate the potency of HMW adiponectin on
AMP-activated protein kinase (AMPK) activation and nuclear
factor (NF)-jB activation.2. Materials and methods
2.1. Cell culture
Human umbilical vein endothelial cells (HUVEC) were obtained
from Clonetics (San Diego, CA, USA) and cultured in EBM medium
supplemented with 5% fetal calf serum in the standard fashion. The
cells in this experiment were used within 3–4 passages and examined
to ensure that they demonstrated the speciﬁc characteristics of endo-
thelial cells. Mouse SVEC4 cells (axillary lymph node, vascular endo-
thelial; SV40 transformed) were also cultured in DMEM containing
10% fetal calf serum and observed to demonstrate the typical cobble-
stone morphological appearance of endothelial cells.
2.2. Western blot analysis
HUVEC were lysed in buﬀer comprising 10 mmol/L Tris (pH 7.4),
100 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L
NaF, 20 mmol/L Na4P2O7, 2 mmol/L Na3VO4, 0.1% SDS, 0.5% so-
dium deoxycholate, 1% Triton-X 100, 10% glycerol, 10 lg/mL leupep-
tin, 60 lg/mL aprotinin, and 1 mmol/L phenylmethanesulfonyl
ﬂuoride. HUVEC lysates were resolved on SDS–PAGE according to
standard protocols. After being transferred to membranes, the samples
were immunoblotted with primary antibodies, followed by secondary
antibodies conjugated with horseradish peroxidase. Bands were re-
vealed using an enzyme-linked chemiluminescence detection kit (Amer-
sham Biosciences, Piscataway, NJ), and density was quantiﬁed with a
LumiVision Analyzer (Aisin, Kariya, Japan). The primary antibodies
used were as follows: anti-phosphorylated AMPKa (Thr-172), anti-
AMPKa, anti-phosphorylated acetyl-CoA carboxylase (ACC) (Ser-
79), anti-ACC, anti-phosphorylated eNOS (Ser-1177) (Cell Signaling
Technology, Beverly, MA), and anti-eNOS monoclonal antibody
(BD Biosciences, San Jose, CA).2.3. Microarray analysis
Microarray analysis of cDNA from the RNA prepared from un-
treated HUVEC or HUVEC treated with HMW adiponectin for 8 h
was performed using Aﬀymetrix GeneChip Expression Analysis (con-
taining oligonucleotide probe sets for approximately 8500 human
genes).
2.4. NF-jB activation
To study NF-jB activation, SVEC4 cells were stably transfected
with a cis-reporter plasmid containing the luciferase reporter gene
linked to ﬁve repeats of NF-jB binding sites (pNFjB-Luc: Stratagene,ation of European Biochemical Societies.
1720 Y. Hattori et al. / FEBS Letters 582 (2008) 1719–1724La Jolla, CA, USA), as previously described [10]. For this, the pNFjB-
Luc plasmid was transfected together with a pSV2neo helper plasmid
(Clontech, Palo Alto, CA, USA) into SVEC4 cells using a FuGEN 6
transfection reagent (Boehringer Mannheim, Mannheim, Germany).
The cells were then cultured in the presence of G418 (Clontech) at a
concentration of 500 lg/mL and the medium was replaced every 2–3
days. Approximately 3 weeks after transfection, G418-resistant clones
were isolated using a cloning cylinder and analyzed individually for
expression of luciferase activity. Several clones were also selected for
analysis of NF-jB activation. Luciferase activity was measured using
a luciferase assay kit (Stratagene).
In order to study NF-jB activation in HUVEC, cells were transfec-
ted with the pNFjB-Luc plasmid at 48 h prior to the experiments.
Constitutively active pCMV-Renilla vectors were used for normaliza-
tion of transfection eﬃciency. The two luciferase signals were assessed
with a dual luciferase assay kit.AMPK
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Fig. 1. HMW adiponectin activates AMPK in vascular endothelial cells.
indicated time periods before lysis, after which cell lysates were probed with a
The chemiluminescence intensity for HMW adiponectin- and gAd-induce
quantiﬁed. (B) HMW adiponectin dose-dependently increase NO production
were expressed as the ratio to the GAPDH, white bar: control, hatched bar2.5. Real-time PCR
For quantitative measurement of mRNA, 2 lg total RNA was trea-
ted with DNase I for 15 min and subsequently used for cDNA synthe-
sis. The PCR reactions using cDNA were performed in a LineGene
system (BioFlux, Tokyo, Japan) under the following conditions:
95 C for 5 min, followed by 40 cycles at 95 C for 15 s, 60 C for
15 s, and 72 C for 30 s.
2.6. siRNA transfection
The day before transfection, plates were inoculated with an appro-
priate number of HUVEC in serum-containing medium to ensure
50–70% conﬂuence the following day. LKB1 siRNA or CaMKKa siR-
NA (Santa Cruz Biotechnology Inc.) mixed with siLentFect (Bio-Rad)
was added to the cells at a concentration of 10 nM. Forty-eight hours
after transfection, AMPK activation induced by HMW adiponectin
was assessed.101.1.01
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Y. Hattori et al. / FEBS Letters 582 (2008) 1719–1724 1721Materials. HMW adiponectin was puriﬁed from human plasma as
previously described [3], which is endotoxin free according to the lim-
ulus test. HMW adiponectin primarily exists as a 18 mer adiponectin.
siRNAs for LKB1, CaMKKa , and eNOS were obtained from Santa
Cruz Biotechnology Inc., BAY 11-7082 was obtained from Biomol
(Plymouth Meeting, PA).
2.7. Statistical analysis
The results are expressed as mean values ± S.D. ANOVA and Fish-
ers least signiﬁcant diﬀerence test were used for multigroup compari-
sons, with a P value of less than 0.05 considered signiﬁcant.3. Results
3.1. Adiponectin activates AMPK in HUVEC
Treatment of HUVEC with HMW adiponectin (10 lg/mL)
resulted in time-dependent activation of AMPK, as monitored
by phosphorylation of AMPK and its down-stream target,
ACC (Fig. 1A). This may have resulted in eNOS phosphoryla-
tion and activation. Indeed, Ser1177 phosphorylation of eNOS
was observed to peak at 2.5 min. Fig. 1A (lower panel) shows
the time course of changes in the chemiluminescence intensity
of AMPK phosphorylation by HMW adiponectin.
We conﬁrmed eNOS activation by HMW adiponectin by
measuring the concentration of bioactive NO in the cellular
supernatant (NOx, as measured by NO
2 and NO3 levels).Fig. 2. (A) HMW adiponectin (Ad) activates AMPK, which was signiﬁcantly
but not with LKB1 siRNA (siL: 10 nM). Inset (lower ﬁgure): 48 h after cells w
levels of LKB1 or CaMKKb were determined. (B) HMW adiponectin (Ad
CaMKKb, STO-609 in HUVEC. Results represent the means ± S.D. (n = 4)Incubation of HUVEC with HMW adiponectin dose-depen-
dently increased NOx concentrations in the culture medium
(Fig. 1B). Examination of the time course showed a substantial
increase in NO production over the course of 1 h, after which
only a modest increase in NO production was observed (data
not shown). The inset in Fig. 1B shows that HWM adiponectin
did not change mRNA levels of eNOS and GTP cyclohydro-
lase (rate limiting enzyme for de novo synthesis of tetrahydro-
biopterin).3.2. CaMKKb mediates AMPK activation upon adiponectin
stimulation
AMPK is controlled by upstream kinases, which have been
identiﬁed as LKB1 or Ca2+/calmodulin-dependent protein ki-
nase b (CaMKKb) [11]. Both LKB1 and CaMKKb are ex-
pressed in HUVEC (data not shown). In order to assess
whether CaMKKb or LKB1 might act as an AMPK kinase
(AMPKK) in adiponectin-stimulated cells, we used an siRNA
approach to knock down the expression of LKB1 or CaM-
KKb. Compared with results following transfection using con-
trol siRNA, HMW adiponectin-induced AMPK activation
was signiﬁcantly reduced in cells treated with CaMKK si
RNA, but not in cells treated with LKB1 siRNA (Fig. 2A).
To further address this question, we performed experiments
with STO-609, a relatively selective inhibitor of CaMKKattenuated in HUVEC transfected with CaMKKb siRNA (siC: 10 nM)
ere transfected with control, LKB1, or CaMKKb siRNA, the mRNA
)-induced AMPK phosphorylation was inhibited by the inhibitor of
. **P < 0.01 vs. AMPK activity by Ad.
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HMW adiponectin-induced AMPK phosphorylation (Fig.
2B).
3.3. Adionectin activates NF-jB
We examined whether HMW adiponectin induces NF-jB
activity in cells. HMW adiponectin was observed to dose-
dependently activate NF-jB-mediated gene transcription101.1
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Fig. 3. The eﬀects of HMW adiponectin and globular adiponectin on
NF-jB-dependent transcriptional activity. (A) SVEC4 cells (transfec-
ted with pNFjB-Luc) were left untreated or were treated with various
concentrations (1–10 lg/mL) of HMW adiponectin. After 2 h, cells
were lysed, and luciferase activity was measured. (B) HMW adipo-
nectin activates NF-jB in SVEC4 cells, which was compared with that
induced by gAd (10 lg/mL), TNFa (10 ng/mL), LPS (1 lg/mL), or IL-
1a (10 ng/mL). (C) HMW adiponectin-induced activation of NF-jB
was signiﬁcantly enhanced in HUVEC treated with L-NMMA (1 mM),
or compound C (10 lM). NF-jB activity was expressed as a ratio of
two signals co-transfected ﬁreﬂy and Renilla luciferases. Results
represent the means ± S.D. (n = 4). **P < 0.01 vs. NF-jB activity by
HMW adiponectin.(Fig. 3A). However, NF-jB-dependent transactivation by
HMW adiponectin at concentration of 10 lg/mL was much
smaller than gAd, TNFa, LPS, and IL-1a (Fig. 3B) compared
to untreated cells. This activation of NF-jB was signiﬁcantly
enhanced by inhibition of NO production with Nx-methyl-L-
arginine (L-NMMA), or AMPK inhibitor compound C (Fig.
3C).
3.4. Eﬀect of adiponectin on B TNFa-Induced NF-jB activation
We then examined pre-treatment of cells with HMW adipo-
nectin on TNFa-induced NF-jB-mediated gene transcription.
In cells pre-treated with HMW adiponectin, TNFa-induced
NF-jB activity was dose-dependently inhibited with greater
inhibition observed with longer periods of incubation (Fig.
4A). Incubation for 16 h with TNFa substantially induced
VCAM-1 gene expression in HUVEC. The degree of induction
of VCAM-1 mRNA by TNFa was modulated by length of
exposure to HMW adiponectin prior to TNFa (data not
shown).ICAM-1 E-selectin
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Fig. 4. (A) The eﬀect of HMW-adiponectin pretreatment on TNFa-
induced NF-jB-dependent transcriptional activity. SVEC4 cells
(transfected with pNFjB-Luc) were treated with various concentra-
tions of adiponectin for 2, 8, or 24 h and then treated with TNFa for
2 h. Then, cells were lysed, and luciferase activities were measured. 2 h-
PI (closed circles), 8 h-PI (closed triangles), and 24 h-PI (closed
squares): preincubation for 2, 8, and 24 h. Data are means ± S.D. of
triplicate observations. (B) Schematic diagram illustrating the pro-
posed eﬀect of HMW adiponectin leading to suppression of TNFa-
stimulated responses in endothelial cells.
Table 1
DNA microarray analysis and real-time PCR
DNA macroarray analysis Real-time PCR
Base (B) signal Exp (E) signal E/B ratio E/B ratio (±S.D.) E/B ratio + BAY11-7082
HMW-adiponectin
ICAM-1 64.1 102.5 1.6 1.85 ± 0.12 0.46 ± 0.06**
E-selectin 7.4 16.2 2.2 2.65 ± 0.29 1.18 ± 0.11**
VCAM-1 6.7 13.4 2.0 2.45 ± 0.09 0.76 ± 0.08**
**P < 0.01 vs. E/B ratio in the absence of BAY11-7082.
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Microarray analysis of cDNA from RNA prepared from un-
treated HUVEC or HUVEC treated with HMW adiponectin
(10 lg/mL) for 8 h was performed using Aﬀymetrix GeneChip
Expression Analysis (containing oligonucleotide probe sets for
approximately 8500 human genes). We found that HMW
adiponectin increased the expression of ICAM-1 (1.6-fold),
E-selectin (2.2-fold), and VCAM-1 (2.0-fold). We conﬁrmed
these increases in mRNA expression by real-time PCR, with
signiﬁcant inhibition of expression observed using the NF-jB
inhibitor BAY11-7082 [13], suggesting that HMW adiponectin
activates NF-jB.4. Discussion
In the present study, we demonstrate that HMW adiponectin
activates AMPK by promoting AMPK phosphorylation.
Although we did not perform a strict kinase assay for AMPK,
we are certain that HMW adiponectin activates AMPK since
the extent of AMPK phosphorylation at Thr-172 strongly re-
ﬂects its activity [14], and since phosphorylation of the AMPK
consensus substrate, ACC, at Ser-79 was also observed. Active
AMPK in turn activates eNOS through phosphorylation of
Ser-1177, which is thought to be the consensus phosphorylation
site of AMPK [15], thereby inducing NO production in HU-
VEC. Thus, AMPK activation by HMW adiponectin appears
to play a protective role against endothelial inﬂammation and
atherogenesis. Our study examines CaMKKb expression and
its functional signiﬁcance with regard to AMPK activation by
adiponectin. Two separate lines of evidence, pharmacological
inhibition of CaMKKb by STO-609 [12] and downregulation
of CaMKKb with speciﬁc targeted siRNA, suggest that CaM-
KKb mediates AMPK activation by adiponectin.
Using microarray analysis we found that HMW adiponectin
increased the expression of ICAM (1.6-fold), E-selectin (2.2-
fold), and VCAM-1 (2.0-fold). This induction of gene expres-
sion is dependent on NF-jB activation, and is signiﬁcantly
inhibited by the NF-jB inhibitor BAY11-7082 [13], suggesting
that HMW adiponectin activates NF-jB. We therefore further
examined whether HMW adiponectin really induces NF-jB
activity in endothelial cells. HMW adiponectin was observed
to dose-dependently activate NF-jB-mediated gene transcrip-
tion. These results suggest that HMW adiponectin possess pro-
inﬂammatory properties. However, this increase in NF-jB
activation was much weaker than the same concentration of
gAd. gAd, a proteolytic cleavage product of adiponectin, ap-
pears to activate vascular endothelial cells [16]. gAd has been
shown to account for less than 1% of the total adiponectin
in blood [17]. Therefore, the biological meaning of adiponectin
should be evaluated in terms of the physiological distributionof its various isoforms, including HMW adiponectin. HMW
adiponectin produced a lesser increase in NF-jB activity than
TNFa, LPS, or IL-1a. The modest nature of this increase in
NF-jB activation may be due, at least in part, to simultaneous
NO production following activation of AMPK/eNOS by
HMW adiponectin. Indeed, when AMPK was inhibited by
compound C or NO production was inhibited by the treatment
with L-NMMA, NF-jB activation signiﬁcantly increased.
We demonstrated that pretreatment with HMW adiponectin
dose-dependently decreased NF-jB activation in accordance
with length of pretreatment. This occurred following an initial
period of activation of NF-jB by adiponectin. Reduced
responsiveness or desensitization to TNFa might occur after
an initial activation during pretreatment. AMPK activation
and/or NO production likely attenuates activation of NF-jB
permitting modest VCAM expression but protecting against
inﬂammatory mediators (Fig. 4B). In fact, a recent report
shows positive associaton of adiponectin with soluble vascular
cell adhesion molecule (sVCAM) levels but negatively with hs-
CRP in patients with vascular disease or dyslipidemia [18].
We previously showed that gAd potently activates NF-jB in
vascular endothelial cells, which in turn induces expression of
proinﬂammatory and adhesion molecule genes [16]. Although
Waki et al. have shown cleavage of adiponectin by leukocyte
elastase secreted from activated monocytes and/or neutrophils
[6], it seems thatminimal amounts of gAd are found even at sites
of inﬂammation. Here, HMW adiponectin was found to mod-
estly activate NF-jB, and appeared to require a shorter pre-
incubation period to inhibit TNFa-induced NF-jB activation,
compared with globular adiponectin. Both gAd and HMW
adiponectin activate AMPK and stimulate NO production.
Thus, both gAd and HMW adiponectin appear to interact with
the same receptors on vascular endothelial cells to activate
AMPK and NF-jB. The manner by which gAd and HMW
adiponectin bind to the receptors, as well as the post-binding
events, likely diﬀers. As we previously showed, antibodies
against the extracellular domains of AdR1 strongly activate
NF-jB [19]. Therefore, how adiponectin stimulates AdR1
should be clariﬁed to understand the mechanism of action of
adiponectin. Under normal conditions, high concentrations of
HWM adiponectin are present in vessels. This indicates that
adiponectin might be protective against inﬂammatory stimuli.
In conclusion, we suggest that HMW adiponectin might
have dual action, both pro and anti-inﬂammatory on vascular
endothelial cells. An initial period of NF-jB activation by
HMW adiponectin might be proinﬂammatory, but it could
lead to a potential reduction in a second activation of NF-
jB in response to inﬂammatory stimuli.Acknowledgement: The authors are grateful to Dr. Kazumi Akimoto
for technical assistance.
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